The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|January 2, 2017
- Pharmaceutical Technology-01-02-2017
- Volume 41
- Issue 1
Automatic Purge System for Control Panels
The Ross SysCon control panels can now be supplied with a fully automatic Type X Purge System, which forces clean air through the enclosure until all hazardous gases are removed.
The Ross SysCon control panels from Ross, Charles & Son can now be supplied with a fully automatic Type X Purge System, which forces clean air through the enclosure until all hazardous gases are removed. The system then maintains a slight positive pressure within the panel. The Type X Purge System includes a 24-volt power supply. The UL-listed Operator Stations are designed for use with a remote PLC System to ensure full operational functionality of the equipment they control.
Articles in this issue
almost 10 years ago
Predicting Moisture Uptake in Solid Dosage Packagingalmost 10 years ago
Blister Packaging Moves Forwardalmost 10 years ago
Staffing and Preparation for Auditsalmost 10 years ago
Fully Automated Capping Systemsalmost 10 years ago
Spray Dryer for Efficient Microencapsulationalmost 10 years ago
Vials Reduce Risk of Drug Container Interactionsalmost 10 years ago
The Tide Stays Highalmost 10 years ago
Drug Quality Key to Innovation and Accessalmost 10 years ago
FDA New Drug Approvals Down Significantly in 2016almost 10 years ago
Beyond Distractions, Pharma Moves OnRelated to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.